Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares saw an uptick in trading volume on Monday . 179,161 shares were traded during trading, an increase of 160% from the previous session’s volume of 68,878 shares.The stock last traded at $3.60 and had previously closed at $3.40.

A number of research firms have recently issued reports on AUPH. Leerink Swann restated an “outperform” rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. HC Wainwright began coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, June 30th. They set a “buy” rating and a $7.00 price target on the stock. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. Finally, Canaccord Genuity restated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, May 12th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $7.15.

The company’s market cap is $116.23 million. The firm’s 50-day moving average is $2.92 and its 200-day moving average is $2.67.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.